Anti-VEGF biosimilar uptake is reshaping retinal commercial dynamics

Reading the signal

The anti-VEGF retinal class includes the established originators (ranibizumab, aflibercept, brolucizumab, faricimab) and increasingly biosimilars. Ranibizumab biosimilars have been on the market in major geographies for several years; aflibercept biosimilars have begun entering the market as the originator's exclusivity periods unwind in different jurisdictions.

The biosimilar uptake patterns are reshaping commercial dynamics:

• Net-pricing pressure on the originator class has been substantial in markets where biosimilar uptake is strong, with implications for revenue trajectories
• Switching from originator to biosimilar varies by market. Markets with strong biosimilar-uptake policies (UK, parts of Europe) have seen rapid switching; the US has seen slower switching driven by the buy-and-bill economics
• The biosimilar conversation has shifted prescriber attention to value-versus-volume metrics in a way that is informing how next-generation assets are being received

For sponsors of next-generation extended-duration retinal assets (faricimab, the high-dose aflibercept formulation, the gene-therapy programs), the commercial environment is structurally different from the one the pivotal trials were designed against. The benefit-on-injection-frequency narrative has to deliver value sufficient to justify the price premium in a market where injection-cost is itself being repriced by biosimilars.

Commercial implications

For sponsors of anti-VEGF originators, biosimilars, and next-generation retinal pipeline:

1. The originator commercial models built around exclusivity-period pricing need to absorb the biosimilar environment. Net-pricing assumptions and the trajectory after biosimilar entry need recalibration in markets where biosimilar penetration is strong
2. The next-generation extended-duration value proposition has to be priced against biosimilar floors, not originator floors. The "fewer injections" narrative is more powerful when the cost-per-injection is set by biosimilars
3. Adjacent retinal indications (geographic atrophy, retinal vein occlusion, diabetic retinopathy) face the same biosimilar dynamic flowing through. The biosimilar effect is structural across the anti-VEGF class

What we are watching

• Aflibercept biosimilar uptake curves in the markets where they have entered, and the rate of uptake in markets where they are imminent
• Pricing data for the next-generation extended-duration retinal assets and the actual net-pricing achievable in the biosimilar-altered market
• Adjacent retinal pipeline launches (geographic atrophy, complement-targeted therapy, gene-therapy programs) and how they navigate the biosimilar dynamic